<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137706">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698281</url>
  </required_header>
  <id_info>
    <org_study_id>AEZS-108-049</org_study_id>
    <nct_id>NCT01698281</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer</brief_title>
  <official_title>A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a therapeutic exploratory Phase 2 study evaluating  AEZS-108  compared to standard
      single agent cytotoxic chemotherapy (SSCC) as measured by the median time of
      progression-free survival (PFS) in patients with chemotherapy refractory triple negative
      (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival.</measure>
    <time_frame>Up to two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AEZS-108</measure>
    <time_frame>Up to two years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response of AEZS-108</measure>
    <time_frame>Up to two years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit of AEZS-108</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of AEZS-108</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of AEZS-108</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of AEZS-108</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AEZS-108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoptarelin doxorubicin</intervention_name>
    <arm_group_label>AEZS-108</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eribulin</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Standard single agent cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women ≥ 18 years of age

          2. Histologically documented breast cancer (either primary or metastatic site) that is
             (i) ER-negative (0), (ii) PR-negative (0), and (iii) HER2-negative, defined by IHC
             (immunohistochemistry; IHC 0/1, non-overexpressing) or FISH (fluorescence in situ
             hybridization; FISH negative) or CISH (chromogen in situ hybridization; CISH
             negative).

          3. Expression of LHRH receptor confirmed by IHC on archival (or current biopsy of breast
             tumor or metastatic site) breast cancer tissue

          4. Progressive disease after failure of 1 to 3 prior chemotherapy regimens for recurrent
             or metastatic (Stage IV) disease (prior adjuvant/neoadjuvant therapy is allowed)

          5. Measurable disease by RECIST 1.1 criteria; at least one target lesion that has not
             been previously irradiated.

        Exclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status &gt; 2

          2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia or recent myocardial infarction (within 6 months of enrollment)

          3. Leptomeningeal disease or brain metastases requiring steroids or other therapeutic
             intervention

          4. Left ventricular ejection fraction (LVEF) &lt; 50 %, determined by echocardiogram or
             MUGA scan

          5. Compromised organ or marrow function as evidenced by any of the following:

               -  thrombocyte count: &lt; 100x109/L

               -  absolute neutrophil count (ANC): &lt; 1.5x109/L

               -  hemoglobin: &lt; 6.0 mmol/L (&lt; 9 g/100 mL)

               -  AS(A)T, AL(A)T: &gt; 2.5 times upper limit of normal range (ULN) (&gt; 5x ULN if
                  clearly related to liver metastases)

               -  bilirubin: &gt; 1.5 mg/dL

               -  creatinine: &gt; 1.5 mg/dL or creatinine clearance &lt; 40 mL/min.

          6. Systemic anticancer therapy or radiotherapy within 21 calendar days of the first dose
             of study drug*)

             * also excluded are patients with anticipated ongoing concomitant anticancer therapy
             during the study

          7. Prior exposure to anthracyclines or anthracenediones for the treatment of metastatic
             breast cancer including liposomal doxorubicin (Doxil), doxorubicin, daunorubicin, or
             mitoxantrone

          8. Prior adjuvant anthracyclines with a cumulative anthracycline dose ≥ 300 mg/m2

          9. Ongoing therapeutic anticoagulation

         10. Patients who are not surgically sterile or post-menopausal must agree to use for the
             duration of the study reliable methods of birth control defined as:

               -  complete abstinence

               -  any intrauterine device (IUD) with published data showing that the lowest
                  expected failure rate is &lt; 1 % per year, or

               -  any other methods with published data showing that the lowest expected failure
                  rate is less than 1 % per year

         11. Investigational therapy within 30 calendar days of the first scheduled day of
             protocol treatment (investigational therapy is defined as treatment for which there
             is currently no regulatory authority approved indication).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto J. Montero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>September 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
